Generation of Allorestricted Antigen Specific T Cells

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses a novel ex vivo method for generating antigen-specific T cells with high functional avidity (affinity), especially tailored for use in adoptive cell therapy against cancer or infectious diseases. The method involves introducing patient-derived MHC genes and target antigens into antigen-presenting cells (like dendritic cells) from a healthy donor. These engineered cells are then used to stimulate donor blood lymphocytes, resulting in the production of T cells that are highly specific for the patient’s MHC-antigen combination and can recognize and attack diseased cells. The patent also covers pharmaceutical compositions of these cells and the use of derived T cell receptors (TCRs) for further engineering transgenic T cells.

Use CasesContent extracted from patent full text and abstract with AI.

• Adoptive cell therapy for treating cancers, including solid tumors (e.g., melanoma, colon, breast, lung) and hematological malignancies (e.g., leukemias, lymphomas).
• Therapeutic intervention against chronic or acute viral infections (e.g., HIV, hepatitis, cytomegalovirus), and other pathogens by generating pathogen-specific T cells.
• Development of personalized cancer immunotherapies based on the patient's unique tumor antigens and MHC alleles.
• Creation of TCR transgenic T cells for off-the-shelf cellular therapeutics tailored to a patient’s tumor or infectious disease profile.
• Reducing graft-versus-host disease (GVHD) risk in cellular therapies by producing highly specific T cells directed only at desired targets, not healthy tissue.
• Regulating unwanted immune responses, for example, using regulatory T cells generated by this technique for autoimmune disease management.

BenefitsContent extracted from patent full text and abstract with AI.

• Allows generation of high-avidity, highly specific T cells that can recognize and efficiently target tumor or pathogen-derived antigens presented on the patient’s own MHC molecules.
• Induces both cytotoxic (CD8+) and helper (CD4+) T cell responses, broadening the immune attack against the disease.
• Overcomes immune tolerance limitations by using allorestricted approaches—every healthy donor pool becomes a source of potent therapeutic T cells for recipients with difficult-to-target antigens.
• Avoids relying solely on known peptide antigens, as whole antigens can be used for stimulation—beneficial for cancers with unknown or complex antigen profiles.
• Decreases the risk of GVHD compared to unselected donor lymphocyte infusions because the T cells are selected for desired antigen/MHC specificity.
• Enables rapid and scalable ex vivo expansion and selection of therapeutic T cells, which is critical for treating fast-growing cancers or serious infections.
• Provides the opportunity to clone and genetically engineer T cell receptors (TCRs) for further personalization or standardization of cell therapies.
• The described approach offers flexibility for targeting a wide range of diseases, from cancer to infectious and autoimmune diseases, using a single underlying platform.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention is directed to a method of generating antigen specific T cells. Furthermore, the invention is directed to antigen specific T cells, isolated transgenic TCR's, pharmaceutical compositions containing same and their use in adoptive cell therapy. This invention in particular pertains to the use of cells co-expressing allogeneic MHC molecules and antigens to induce peptide-specific T cells from non-selected allogeneic T cell repertoires.